{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:05Z","timestamp":1792784825842,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00228-026-04199-0","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:44:49Z","timestamp":1792723489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications"],"prefix":"10.1007","volume":"82","author":[{"given":"Rachelle","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caden","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"9733","key":"4199_CR1","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"R Emerging","year":"2010","unstructured":"Emerging R, Factors C et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733):2215\u20132222","journal-title":"Lancet"},{"issue":"24","key":"4199_CR2","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545\u20132559","journal-title":"N Engl J Med"},{"issue":"21","key":"4199_CR3","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM et al (2021) Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 143(21):e984\u2013e1010","journal-title":"Circulation"},{"issue":"1","key":"4199_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"GBDO Collaborators","year":"2017","unstructured":"Collaborators GBDO et al (2017) Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 377(1):13\u201327","journal-title":"N Engl J Med"},{"issue":"4","key":"4199_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab 27(4):740\u2013756","journal-title":"Cell Metab"},{"issue":"24","key":"4199_CR6","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N et al (2022) GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation 146(24):1882\u20131894","journal-title":"Circulation"},{"issue":"24","key":"4199_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"2","key":"4199_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V et al (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 391(2):109\u2013121","journal-title":"N Engl J Med"},{"issue":"20","key":"4199_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK et al (2025) Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med 392(20):2001\u20132012","journal-title":"N Engl J Med"},{"issue":"5","key":"4199_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M et al (2025) Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 392(5):427\u2013437","journal-title":"N Engl J Med"},{"issue":"24","key":"4199_CR11","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ et al (2025) Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 393(24):2409\u20132420","journal-title":"N Engl J Med"},{"issue":"3","key":"4199_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14740338.2017.1281246","volume":"16","author":"NB Dalsgaard","year":"2017","unstructured":"Dalsgaard NB et al (2017) Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opin Drug Saf 16(3):351\u2013363","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"4199_CR13","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci 17(8):2050\u20132068","journal-title":"Int J Biol Sci"},{"key":"4199_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-021-01385-5","volume":"20","author":"A Natali","year":"2021","unstructured":"Natali A et al (2021) Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol 20:196","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"4199_CR15","first-page":"e68390","volume":"16","author":"K Hamed","year":"2024","unstructured":"Hamed K et al (2024) Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review. Cureus 16(9):e68390","journal-title":"Cureus"},{"issue":"4","key":"4199_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"19","key":"4199_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"10193","key":"4199_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"23","key":"4199_CR19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA et al (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373(23):2247\u20132257","journal-title":"N Engl J Med"},{"issue":"13","key":"4199_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR et al (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 377(13):1228\u20131239","journal-title":"N Engl J Med"},{"issue":"1","key":"4199_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","volume":"28","author":"CT Ruff","year":"2022","unstructured":"Ruff CT et al (2022) Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med 28(1):89\u201395","journal-title":"Nat Med"},{"issue":"10","key":"4199_CR22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7(10):776\u2013785","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"4199_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653\u2013662","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"4199_CR24","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE et al (2024) Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med 30(10):2849\u20132856","journal-title":"Nat Med"},{"issue":"11","key":"4199_CR25","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2337\/dc25-0472","volume":"48","author":"P Rossing","year":"2025","unstructured":"Rossing P et al (2025) Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis. Diabetes Care 48(11):1878\u20131887","journal-title":"Diabetes Care"},{"issue":"6","key":"4199_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP et al (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385(6):503\u2013515","journal-title":"N Engl J Med"},{"issue":"1","key":"4199_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ et al (2025) Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 393(1):26\u201336","journal-title":"N Engl J Med"},{"issue":"8","key":"4199_CR28","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1111\/dom.70888","volume":"28","author":"M De Fano","year":"2026","unstructured":"De Fano M et al (2026) GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology. Diabetes Obes Metab 28(8):6509\u20136532","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"4199_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN et al (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 389(12):1069\u20131084","journal-title":"N Engl J Med"},{"issue":"4","key":"4199_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","volume":"86","author":"BA Borlaug","year":"2025","unstructured":"Borlaug BA et al (2025) Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial. J Am Coll Cardiol 86(4):242\u2013255","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4199_CR31","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski G et al (2018) The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-\/-) and LDLr(-\/-) Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci 3(6):844\u2013857","journal-title":"JACC Basic Transl Sci"},{"issue":"7","key":"4199_CR32","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2337\/dc19-2251","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB et al (2020) Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care 43(7):1546\u20131552","journal-title":"Diabetes Care"},{"issue":"10516","key":"4199_CR33","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield J et al (2025) Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 406(10516):2257\u20132268","journal-title":"Lancet"},{"issue":"20","key":"4199_CR34","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1001\/jama.2025.15841","volume":"334","author":"MJ Klebanoff","year":"2025","unstructured":"Klebanoff MJ et al (2025) Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists. JAMA 334(20):1848\u20131850","journal-title":"JAMA"},{"issue":"25","key":"4199_CR35","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","volume":"138","author":"JFE Mann","year":"2018","unstructured":"Mann JFE et al (2018) Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation 138(25):2908\u20132918","journal-title":"Circulation"},{"issue":"11","key":"4199_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH et al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"4199_CR37","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc23-S013","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA et al (2023) 13. Older Adults: Standards of Care in Diabetes-2023. Diabetes Care 46(Suppl 1):S216\u2013S229","journal-title":"Diabetes Care"},{"issue":"10454","key":"4199_CR38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J et al (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 404(10454):773\u2013786","journal-title":"Lancet"},{"issue":"10456","key":"4199_CR39","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(24)01763-X","volume":"404","author":"C Hage","year":"2024","unstructured":"Hage C (2024) GLP-1 receptor agonists in heart failure: how far to expand use? Lancet 404(10456):909\u2013911","journal-title":"Lancet"},{"issue":"1","key":"4199_CR40","doi-asserted-by":"publisher","first-page":"e001986","DOI":"10.1136\/bmjopen-2012-001986","volume":"3","author":"LE Robinson","year":"2013","unstructured":"Robinson LE et al (2013) Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3(1):e001986","journal-title":"BMJ Open"},{"issue":"11","key":"4199_CR41","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ et al (2022) Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45(11):2753\u20132786","journal-title":"Diabetes Care"},{"key":"4199_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","volume":"229","author":"DH Ryan","year":"2020","unstructured":"Ryan DH et al (2020) Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J 229:61\u201369","journal-title":"Am Heart J"},{"issue":"39","key":"4199_CR43","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"4199_CR44","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA et al (2023) 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 46(Suppl 1):S158\u2013S190","journal-title":"Diabetes Care"},{"issue":"1","key":"4199_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M et al (2017) Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation 136(1):6\u201319","journal-title":"Circulation"},{"issue":"4","key":"4199_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263\u2013271","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"4199_CR47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB et al (2016) Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 316(5):500\u2013508","journal-title":"JAMA"},{"issue":"1","key":"4199_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69\u201377","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"4199_CR49","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-011-2440-x","volume":"55","author":"D Nathanson","year":"2012","unstructured":"Nathanson D et al (2012) Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 55(4):926\u2013935","journal-title":"Diabetologia"},{"issue":"25","key":"4199_CR50","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1056\/NEJMoa1503840","volume":"374","author":"G Twig","year":"2016","unstructured":"Twig G et al (2016) Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med 374(25):2430\u20132440","journal-title":"N Engl J Med"},{"issue":"10511","key":"4199_CR51","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0140-6736(25)01774-X","volume":"406","author":"TS Hannon","year":"2025","unstructured":"Hannon TS et al (2025) Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 406(10511):1484\u20131496","journal-title":"Lancet"},{"issue":"9","key":"4199_CR52","doi-asserted-by":"publisher","first-page":"e023811","DOI":"10.1161\/JAHA.121.023811","volume":"11","author":"R Adhikari","year":"2022","unstructured":"Adhikari R et al (2022) National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020. J Am Heart Assoc 11(9):e023811","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"4199_CR53","doi-asserted-by":"publisher","first-page":"e2540890","DOI":"10.1001\/jamanetworkopen.2025.40890","volume":"8","author":"P Li","year":"2025","unstructured":"Li P et al (2025) Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity. JAMA Netw Open 8(10):e2540890","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"4199_CR54","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc23-S008","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA et al (2023) 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 46(Suppl 1):S128\u2013S139","journal-title":"Diabetes Care"},{"issue":"18","key":"4199_CR55","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"22S","key":"4199_CR56","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1016\/j.jacc.2026.03.056","volume":"87","author":"CE Ndumele","year":"2026","unstructured":"Ndumele CE et al (2026) 2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome. J Am Coll Cardiol 87(22S):e1889\u2013e2007","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"4199_CR57","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 24(8):1553\u20131564","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"4199_CR58","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM et al (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514\u2013526","journal-title":"N Engl J Med"},{"issue":"10403","key":"4199_CR59","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP et al (2023) Efficacy and safety of co-administered once-weekly cagrilintide 2.4\u00a0mg with once-weekly semaglutide 2.4\u00a0mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 402(10403):720\u2013730","journal-title":"Lancet"},{"issue":"12","key":"4199_CR60","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Frias","year":"2016","unstructured":"Frias JP et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4(12):1004\u20131016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4199_CR61","unstructured":"ClinicalTrials.gov. (2022). A Study of tirzepatide (LY3298176) on the reduction on morbidity and mortality in adults with obesity (SURMOUNT-MMO). NCT05556512. https:\/\/clinicaltrials.gov\/study\/NCT05556512"},{"key":"4199_CR62","unstructured":"ClinicalTrials.gov. (2022). A study of tirzepatide in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes (TREASURE-CKD). NCT05536804. https:\/\/clinicaltrials.gov\/study\/NCT05536804"},{"key":"4199_CR63","unstructured":"ClinicalTrials.gov. (2024). The effect of retatrutide once weekly on cardiovascular outcomes and kidney outcomes in adults living with obesity (TRIUMPH-Outcomes). NCT06383390. https:\/\/clinicaltrials.gov\/study\/NCT06383390"},{"key":"4199_CR64","unstructured":"ClinicalTrials.gov. (2025). Evaluating the impact of maridebart cafraglutide on cardiovascular outcomes in participants with atherosclerotic cardiovascular disease and overweight or obesity (MARITIME-CV). NCT07037433. https:\/\/clinicaltrials.gov\/study\/NCT07037433"},{"issue":"10","key":"4199_CR65","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C et al (2016) Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care 39(10):1702\u20131710","journal-title":"Diabetes Care"},{"issue":"22","key":"4199_CR66","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS et al (2020) A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 382(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"24","key":"4199_CR67","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D et al (2022) Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med 387(24):2245\u20132257","journal-title":"N Engl J Med"},{"issue":"25","key":"4199_CR68","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139(25):e1082\u2013e1143","journal-title":"Circulation"},{"issue":"30","key":"4199_CR69","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/eurheartj\/ehw172","volume":"37","author":"S Blankenberg","year":"2016","unstructured":"Blankenberg S et al (2016) Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J 37(30):2428\u20132437","journal-title":"Eur Heart J"},{"issue":"10455","key":"4199_CR70","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(24)01356-4","volume":"404","author":"JL Dellgren","year":"2024","unstructured":"Dellgren JL, Persad G, Emanuel EJ (2024) International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches. Lancet 404(10455):902\u2013906","journal-title":"Lancet"},{"issue":"10113","key":"4199_CR71","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","volume":"390","author":"NCDRF Collaboration","year":"2017","unstructured":"Collaboration NCDRF (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 390(10113):2627\u20132642","journal-title":"Lancet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04199-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04199-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04199-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:01:51Z","timestamp":1792782111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04199-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4199"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04199-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","label":"Human ethics and consent to participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"276"}}